Synthesis of 5-O- and 6-O-Methyldihydrostreptomycin

Teruo Kishi, Tsutomu Tsuchiya,* Naokazu Koga, Yoshihiko Kobayashi, and Sumio Umezawa

Institute of Bioorganic Chemistry, 1614 Ida, Nakahara-ku, Kawasaki 211

(Received May 10, 1985)

5-O- and 6-O-Methyldihydrostreptomycin have been prepared from dihydrostreptomycin by a sequence of reactions involving methylation of a selectively protected derivative (4) with diazomethane in the presence of tin(II) chloride. The structures of the final products were confirmed by their ¹³C-NMR spectra and the TACu method.

Streptomycin is inactivated by resistant bacteria^{1,2,3)} producing inactivating enzymes: AAD(3") or APH(3") which adenylylates or phosphorylates the 3"-hydroxyl group, and AAD(6) or APH(6) which adenylylates or phosphorylates the 6-hydroxyl group of streptomycin and dihydrostreptomycin† to give the corresponding O-adenylyl or O-phosphoryl compounds. counteract the action of the enzymes AAD(3") or APH(3"), 3"-deoxydihydrostreptomycin^{4,5,6)} and 3"epidihydrostreptomycin^{7,8)} had been prepared. These compounds showed satisfactory activities against the resistant bacteria owing to the lack of the equatorial 3"-hydroxyl group to be modified. Another device for the enzymes AAD(6) or APH(6), however, was unsuccessful. Chemically prepared 6deoxydihydrostreptomycin⁹⁾ showed only very weak antibacterial activity, suggesting that the 6-hydroxyl group plays an important role in the mechanism of antibacterial action. In connection with our interest in the structure-activity relationships, in this paper, we have described the synthesis of 5-O- and 6-Omethyldihydrostreptomycin (9 and 10). The former derivative (9) was prepared to determine the steric influence of the neighboring substituent on the 6modifying mechanism.

Tris(NG,NG,N-benzyloxycarbonyl)dihydrostreptomycin (1),10) the starting compound, was treated with p-tolualdehyde dimethyl acetal in the presence of acid catalyst under strictly dry conditions. Tris $(N^G, N^G, N - \text{benzyloxycarbonyl}) - 5, 6:3', 3'a:4'', 6'' - \text{tris}(O - S)$ p-methylbenzylidene)dihydrostreptomycin (2) was obtained with slight accompanied mono-, di-, and overacetalated derivatives. Chromatographic separation gave the pure 2. In this acetal-exchange reaction, formations of N^{G} , O-acetals such as 3,3'a:4", 6"-bis(O-p-methylbenzylidene)- N^{G} ,O-(p-methylbenzylidene) derivatives bearing cyclic bridges between 1- N^{G} , 2-O, 2-O, 3- N^{G} , or 1- N^{G} , 6-O, were also suspected. Formation of such type of compounds was found¹¹⁾ in the reaction of 2-guanidino-1-cyclohexanols with 1,1-dimethoxycyclohexane (in N,N-dimethylformamide

in the presence of *p*-toluenesulfonic acid). In the above case, however, they were successfully removed in the purification step.

	\mathbb{R}^1	\mathbb{R}^2	R³	R4
DHSM	$NHC(=NH)NH_2$	Н	H	Н
1	$NHC(=NZ)NH_2^{19}$	H	H	\mathbf{Z}
9	$NHC(=NH)NH_2$	Me	H	Η
10	$NHC(=NH)NH_2$	H	Me	Η
11	NH ₂	Me	H	Η
12	NH_2	H	Me	Η
13	NH_2	H	H	H

$$\begin{array}{c} \text{NHC}(=NZ)\text{NHR}^1\\ \text{OR}^1\\ \text{NHC}(=NZ)\text{NHR}^1\\ \\ \text{NHC}(=NZ)\text{NHR}^1\\ \\ \text{OP}^1\\ \\ \text{OP}$$

	R1	R ²	R³
2	Н	CHC ₆ I	$H_4Me(p)$
3	\mathbf{Ac}	CHC ₆ I	$H_4Me(p)$
4	\mathbf{Ac}	H	Н
5	Ac	Me	H
6	\mathbf{Ac}	Η	Me
7	H	Me	H
В	H	H	Me
Z =	C_6H_5C	H ₂ OCO-	-

[†] As the name dihydrostreptomycin has been widely used, we have used this trivial name.

Acetylation of **2** with acetic anhydride in pyridine gave the tetraacetate (**3**), the positions of the acetyl groups being estimated 1,3-N^G,N^G and 2,3"-O,O. Selective deacetalation of **3** in a medium containing acetic acid gave the corresponding 5,6-O-deacetalated derivative (**4**) in a moderate yield. Careful methylation of **4** with diazomethane in the presence¹²⁾ of tin(II) chloride gave a mixture of 5-O and 6-O-methyl derivatives (**5** and **6**), which, without purification, deacetylated (to give **7** and **8**). Treatment of the product mixture with sodium in liquid ammonia (to remove the *p*-methylbenzylidene and benzyloxycarbonyl groups) followed by repeated chromatography gave 5-O- and 6-O-methyldihydrostreptomycin (**9** and **10**).

The structures of the final products were determined by the 13 C-NMR spectra (Table 1). Since dihydrostreptomycin gave well-separated signals at pD \approx 6, the spectra of the minor (9) and the major (10) products were measured at the same pD. The 13 C signals of 9 and 10 except for C-5,6 were both readily assigned on the basis of comparison of the corresponding chemical shifts of dihydrostreptomycin. 13 The remaining resonances of the minor product (9) were those at δ 83.8 and 71.9, and of the major (10), at δ 73.7 and 82.5. Since C-5 and C-6 of dihydrostreptomycin resonated 13 0 at δ 74.2 and 72.4 at pD \approx 6,

Table 1. The 13 C chemical shifts $^{a)}$ of **9**, **10** and dihydrostreptomycin dissolved in D_2 O at pD $6^{b)}$

			.
Carbon	9	10	Dihydrostrepto- mycin ¹³⁾
C-1	59.6	58.7	59.8
C-2	71.4	71.3	71.5
C-3	59.4	59.1	59.1
C-4	76.0	77.9	78.7
C-5	83.8	73.7	74.2
C- 6	71.9	82.5	72.4
C-1'	106.7	106.3	106.7
C-2'	84.4	85.2	84.9
C-3'	81.6	81.5	81.7
C-3'a	64.4	64.3	64.2
C-4'	79.0	78.8	78.5
C-5'	13.6	13.5	13.5
C-1"	94.1	94.6	94.4
C-2"	62.0	62.0	62.1
C-3"	70.3	70.3	70.3
C-4"	70.1	70.1	70.3
C-5"	73.6	73.6	73.6
C-6"	61.3	61.3	61.3
$C(1)NHC(=NH)NH_2$	159.0	158.8	159.2
$C(3)NHC(=NH)NH_2$	158.3	158.5	158.6
NCH_3	32.7	32.7	32.8
OCH_3	60.9	61.2	

a) In ppm downfield from TMS calculated as $\delta^{\text{TMS}} = \delta^{\text{dloxane}} + 67.4 \text{ ppm.}$ b) Adjusted by addition of DCl.

respectively, the signals at δ 71.9 of **9** and δ 73.7 of **10** were assigned to C-6 and C-5 of the respective compounds. The signals of $80'(\delta)$ of **9** and **10** were, therefore, assigned to the resonances of C-5 and C-6 carrying the OMe groups of the respective compounds, the chemical shifts being typical¹⁴⁾ for the carbons carrying an ether group. Furthermore, as the results of the negative shift effect of O-methylation at the neighboring positions, 14) the signals of C-4 and C-6 of 9, and C-1 and C-5 of 10 were respectively shifted upfield, compared to the chemical shifts of the corresponding carbons of dihydrostreptomycin. Thus, the major (10) and the minor (9) methylated products were determined 6-O- and 5-O-methyldihydrostreptomycin, respectively. These results, in turn, supported that 3 had 5,6-O- and not NG,Obenzylidene structure, as already described.

The structures of **9** and **10** were confirmed by the tetraamminecopper(II) (TACu)§ method^{15,16)} on their deamidino derivatives (Table 2). Deamidination of 9, 10 and dihydrostreptomycin according to Polglase¹⁷⁾ gave the corresponding 1,3-diamino derivatives (11, 12, and 13¹⁷⁾). 1,3-Di(deamidino)-5-O-methyldihydrostreptomycin (11) and 13 showed similar ∆[M]_{TACu} and $\Delta[M]_{TACu-NH_3}$ values owing to the lack of participation for complexing including the functional groups at C-5, although, in 11, the proportion of the complexing like B (see Fig. 1) seemed to be slightly less than that in 13, In 1,3-di(deamidino)-6-O-methyldihydrostreptomycin (12), the degree of the A-type complex in TACu solution was considered to be essentially the same with the complexings of the other compounds (11 and 13). However, after addition of ammonia, complexing could occur both at $NH_2(1)-OH(2)(sign-)$ and $OH(2)-NH_2(3)(sign+)$ competitively, thus showing the value as expected from the apparent complexing formed only at NHCH₃(2")-OH(3")(see Fig. 2).

The antibacterial spectra of **9** and **10** showed that they had only very slight activities, suggesting that

[§] TACu can form complex only with a pair of vicinal amino and hydroxyl groups having relative special orientations of ≈60° dihedral angle and the ∆[M]_{TACu}(= [M]_{TACu}=[M]_{H2O}) shows a value of ±900°, the sign being decided by counterclockwise (positive) or clockwise (negative) orientation in the Newman projection of $-(NH_2)$ CH-CH(OH)-. In the case of 13, TACu forms complexes mainly at NHMe(2")-OH(3")(sign+) and NH₂(1)-OH(2)-(sign-) to give roughly cancelled value (+34016), and by slight addition of ammonia to the TACu solution, 16) the latter complex almost disappeared and, instead, two new complexes at $OH(2)-NH_2(3)(sign+)$ and $NH_2(1)-OH(6)$ -(sign+) appeared, to result in giving a large positive value of $\Delta[M]_{TACu-NH_3}(+2530^{16})$. This phenomenon was interpreted by the assumption that TACu made complexes in streptamine portion of 13 in a state of equilibrium as depicted in Fig 1.16)

Fig. 1.

In TACu a mixture of 1,2-(type A, $\approx 73\%$) and 2,3-complexes(type B, $\approx 27\%$) was expected, and in TACu-NH₃, 1,2-($\approx 46\%$) and 2,3-complexes($\approx 54\%$).

Fig. 2.

Table 2. $\Delta[M]_{TACU}$ values of 11, 12, and 1317) before and after addition of ammonia

	[M] _{H2O}	$[\mathbf{M}]_{\mathtt{TACu}^{\mathbf{a})}$	∆[M] _{TACu}	[M] _{TACu-NH3} b)	△[M] _{TACu-NH3}
11	-1110	-760	+ 350	+920	+2030
12	-1410	-930	+480	-440	+970
13	-1260	1000	+260	+1380	+2600

a) 0.01 mmol of each sample (as the hydrogencarbonate) was dissolved in 1.0 ml of 0.16 mmol TACu solution and the rotation of the solution was measured in 0.1 dm tube at 436 nm. ¹⁶⁾ b) After measuring the [M]_{TACu}, 0.001 ml each of 15 mol dm⁻³ ammonium hydroxide solution was added to the solution (0.55 mol) and the rotation of the solution was again measured. The procedure was repeated until the rotation reached to a constant value. ¹⁶⁾

masking of the hydroxyl at C-5 or C-6 both greatly influences the binding of the antibiotic to the bacterial ribosome.

Experimental

General. ¹H-NMR spectra were recorded at 90 MHz with a Varian EM-390 spectrometer except for **9** and **10**, the spectra of which being recorded at 250 MHz in the FT mode with a Bruker WM 250 spectrometer. ¹³C-NMR spectra were recorded in the FT mode with a Bruker WM 250 spectrometer operating at 62.5 MHz. Thin-Layer chromatography (TLC) was performed on Wakogel B5. For column chromatography, silica gel (Wakogel C-200)

was used.

1,3,2"-Tris(N^G,N^G,N-benzyloxycarbonyl)-5,6:3',3'a:4",6"-tris(Op-methylbenzylidene)dihydrostreptomycin (2). To a solution of 1 (6.0 g) in dry N,N-dimethylformamide (120 ml) were added p-tolualdehyde dimethyl acetal (24 ml) and molecular sieves 5A (6 g) and, after stirring for 30 min, was added anhydrous p-toluenesulfonic acid (3 g), and the mixture was stirred at 60 °C for 5 h under reduced pressure (≈15 Torr (1 Torr=133.322 Pa); to remove the methanol liberated). The solution was poured into a saturated aqueous sodium hydrogencarbonate solution (27 ml) and the precipitates were filtered off with aid of methanol. (If the addition of the reaction mixture to the alkaline solution is reversed, yield of 2 sometimes greatly decreased

owing to removal of the 5,6-acetal group.) The filtrates and washings combined were concentrated to give a syrup, that was extracted with chloroform. The organic solution was washed with saturated aqueous sodium chloride, dried (Na₂SO₄), and concentrated. Addition of hexane to the concentrate gave a solid (\approx 6 g). Purification of the solid by silica-gel column chromatography with benzene–ethanol-triethylamine (30:1:0.1) as the developer gave an amorphous solid of **2**, 3.18 g (41%), $[\alpha]_D^{25}$ –64° (c 1, chloroform). ¹H-NMR (CDCl₃) δ =1.2—1.4 [3H, CH₃(5')], 2.3 (9H br s, 3 CH₂CH₄₋₁)

Found: C, 64.12; H, 6.01; N, 7.59%. Calcd for C₆₉H₇₇N₇O₁₈: C, 64.19; H, 6.01; N, 7.40%.

1,3-Di-N^G-acetyl-2,3"-di-O-acetyl-1,3,2"-tris(N^G,N^G,N-benzyloxy-carbonyl)-5,6:3',3'a:4",6"-tris(O-p-methylbenzylidene)dihydro-streptomycin (3). A mixture of **2** (900 mg) and acetic anhydride (4.8 ml) in pyridine (13.5 ml) was kept at room temperature overnight. Pouring the solution into ice water (100 ml) gave precipitates, that was thoroughly washed with water, then dried to give a solid of **3**, 1.00 g (99%), TLC (benzene-ethanol=15:1): R_1 =0.75 (cf. **2**: 0.2), $[\alpha]_D^{20}$ -37° (c 1, chloroform).

¹H-NMR (CDCl₃) δ =1.2—1.4 [3H, CH₃(5')], 1.9—2.2 (12H, mainly 4 singlets with different strength, 4Ac), 2.4 (9H, s, 3CH₃C₆H₄–), 2.74 (3H, s, NCH₃).

Found: C, 63.06; H, 5.95; N, 6.46%. Calcd for $C_{77}H_{85}N_7O_{22}$; C, 63.32; H, 5.86; N, 6.71%.

1,3-Di-N^G-acetyl-2,3"-di-O-acetyl-1,3,2"-tris(N^G,N-G,N-benzyloxy-carbonyl)-3',3'a:4",6"-bis(O-p-methylbenzylidene)dihydrostreptomycin (4). A solution of 3 (1062 mg) in a mixture of 1,4-dioxane (25 ml) and 50% aqueous acetic acid (25 ml) was allowed to stand at room temperature for 4 h. The solution was poured, with careful agitation, into water (100 ml) containing sodium hydrogencarbonate (20 g) and the mixture extracted with chloroform. The extract, after dried (Na₂SO₄), was concentrated to give a residue, that contained three products, on checking by TLC (benzene-ethanol=15:1), having R_f 0.25 (slight), 0.17 (4, major), and 0.12 (slight). Separation with silica-gel column chromatography with benzene-ethanol-triethylamine (30:1:0.05) gave a solid of 4, 634 mg (64%), $[\alpha]_D^{20}$ -38° (c 1, chloroform).

¹H-NMR (CDCl₃) δ =≈1.3 [3H, CH₃(5')], 1.9—2.2 (12H, mainly 3 peaks, including unresolved, small strength, 4Ac), 2.4 (6H s, 2CH₃C₆H₄–), 2.74 (3H br s, NCH₃).

Found: C, 60.77; H, 6.02; N, 7.06%. Calcd for $C_{69}H_{79}N_7O_{22}$: C, 61.01; H, 5.86; N, 7.22%.

Reaction of 4 with Diazomethane. To an ice-cold solution of 4 (240 mg) in methanol (2.7 ml) containing $SnCl_2 \cdot 2H_2O$ (8 mg, 0.2 mol equiv for 4) was added diazomethane in ether¹⁸⁰ in small portions, and the reaction was monitored by TLC (benzene-ethanol=7:1). After 20 ml addition of the ether solution, the starting 4 (R_1 = 0.37) almost disappeared and the products (5, 6, R_1 = 0.43) appeared. Concentration gave a residue, that was extracted with chloroform. The extract was washed thoroughly with water, dried (Na₂SO₄), and concentrated to give a solid (232 mg). The ¹H-NMR (CDCl₃) spectrum of the products gave a clear peak at δ =3.6 (OMe).

5-O- and 6-O-Methyldihydrostreptomycin (9 and 10). A crude mixture of 5 and 6 (220 mg) dissolved in methanol (22 ml) containing 15 M aqueous ammonia (0.44 ml)(1 $M=1 \, \mathrm{mol} \, \mathrm{dm}^{-3}$) was kept at room temperature for 1 h.

Concentration gave a residue (190 mg), that was purified by silica-gel column chromatography with benzene-ethanol (15:1) to give a mixture of 7 and 8 (125 mg). In the ¹H-NMR spectrum, no peak was observed near δ =2 (Ac). A solution of the mixture (115 mg) in oxolane (1.5 ml) was gradually poured into a solution of sodium (≈60 mg) in liquid ammonia (15 ml) maintained at -60 °C, and the blue solution was kept at the temperature for 1.5 h. Addition of methanol until the color disappeared was followed by raising the temperature until 30 °C in order to evaporate the ammonia. The residue was then neutralized with 1M aqueous hydrochloric acid and charged on a column of Amberlite CG 50 (NH₄ form, 20 ml). After washing the column with water, the products were eluted by aqueous ammonium carbonate solution (1-5%, the concentration was gradually changed) and the portion positive for biacetyl color test (indication for the presence of guanidino group) was collected and repeatedly concentrated with several additions of water to remove ammonium carbonate to give a solid (a mixture of 9 and 10. 32 mg). The mixture was dissolved in 50% aqueous acetic acid (0.6 ml) and separated by column chromatography of microcrystalline cellulose powder (Avicel SF, 15g, Funakoshi Co., Tokyo) with 1-butanol-pyridine-wateracetic acid (6:4:3:1). Fractions containing 9 and 10 were, respectively, concentrated, and the residue was purified by a column of Amberlite CG 50 (NH₄ form) with 5% aqueous ammonium carbonate. The fractions positive for biacetyl were repeatedly concentrated with several additions of water (to remove (NH₄)₂CO₃) to give, after drying, solids of **9**, 6.5 mg (5% based on **4**) and **10**, 18.5 mg (15% based on **4**), each as the carbonate.

9: $[\alpha]_D^{20} - 79^{\circ}$ (c 0.8, water).

¹H-NMR (D₂O, the hydrogencarbonate salt) δ=1.25 [3H d, J=7 Hz, CH₃(5')], 2.43 (3H s, NCH₃), 2.62 (1H dd, H-2"), 3.33 (1H unresolved t, H-5) 3.62 (3H s, OCH₃), 3.83 (1H dd, J=4.8 and 12 Hz) and 3.92 (1H dd, J=2 and 12 Hz)(H-6,6'), 4.225 (1H d, H-2'), 4.27 (1H q, J=7 Hz, H-4'), 5.26 (1H d, H-1"), and 5.29 (1H d, H-1'); $J_{1'',2'}$ =1, $J_{1'',2''}$ =3, and $J_{2'',3''}$ =11 Hz. ¹H-NMR (D₂O+DCl; pD<1) δ=1.24 [3H d, CH₃(5')], 2.89 (3H s, NCH₃), 3.32 (1H, H-5), 3.35 (1H dd, H-2"), 3.60 (3H s, OCH₃), 4.25 (1H q, H-4'), 4.305 (1H d, H-2'), 5.28 (1H d, H-1'), and 5.57 (1H d, H-1"); J values were the same with those of the

hydrogencarbonate. Found: C, 39.95; H, 6.67; N, 13.55%. Calcd for C₂₂H₄₃N₂₇O₁₂·2H₂CO₃: C, 39.94; H, 6.56; N, 13.59%.

10: $[\alpha]_D^{20}$ -88° (c 1, water).

¹H-NMR (D₂O, the hydrogencarbonate salt) δ=1.24 [3H d, J=7 Hz, CH₃(5′)], 2.41 (3H s, NCH₃), 2.61 (1H dd, H-2″), 3.24 (1H unresolved t, H-6), 3.59 (3H s, OCH₃), 3.83 (1H dd, J=4.8 and 12 Hz) and 3.93 (1H dd, J=2 and 12 Hz)(H-6,6′), 4.205 (1H d, H-2′), 4.30 (1H q, J=7 Hz, H-4′), 5.23 (1H d, H-1″), and 5.29 (1H d, H-1′); J_{1′′,2′}=1, J_{1′′,2′′}=3, and J_{2″,3′′}=11 Hz.

¹H-NMR (D₂O+DCl, pD>1) δ =1.24 [3H d, CH₃(5')], 2.90 (3H s, NCH₃), 3.25 (1H unresolved t, J=≈8 Hz, H-6), 3.36 (1H dd, H-2"), 3.60 (3H s, OCH₃), 4.30 (1H q, H-4'), 4.32 (1H d, H-2'), 5.31 (1H d, H-1'), and 5.58 (1H d, H-1").

Found: C, 37.65; H, 6.52; N, 12.91%. Calcd for C₂₂H₄₃N₂₇O₁₂·2H₂CO₃·2H₂O: C, 37.50; H, 6.84; N, 13.04%.

Alkaline Degradation¹⁰ of 9, 10, and Dihydrostreptomycin. The hydrogenearbonate salts of 9, 10, and dihydostrepto-

mycin (20 mg each) were respectively treated in the same manner as reported¹⁷⁾ (1 ml of 90% saturated aqueous barium hydroxide, refluxing for 28 h), and the products were purified by a Dowex 1×2 (OH⁻ form) resin column with water to give chromatographycally homogeneous (TLC, with chloroform-ethanol-17% aqueous ammonia= 2:2:1), ninhydrin positive, diacetyl and Ehrlich negative, solids of 11 (16 mg*, R_f =0.52), 12 (15 mg*, R_f =0.65) and 13¹⁷⁾ (16 mg, R_f =0.31).

We are grateful to Professor Hamao Umezawa of Institute of Microbial Chemistry for the discussions, support and encouragements.

References

- 1) H. Umezawa, Adv. Carbohydr. Chem. Biochem., 30, 183 (1974).
- 2) J. Davies, and S. O'Connor, Ann. Rev. Microbiol., 32, 469 (1978).
- 3) H. Umezawa and S. Kondo, "Aminoglycoside Antibiotics," ed by H. Umezawa and I. R. Hooper, Springer-Verlag, Berlin, Heidelberg, New York (1982) p. 267—292.
- 4) H. Sano, T. Tsuchiya, S. Kobayashi, M. Hamada, S. Umezawa, and H. Umezawa, J. Antibiot., 29, 978 (1976).

- 5) T. Usui, T. Tsuchiya, H. Umezawa, and S. Umezawa, Bull. Chem. Soc. Jpn., 54, 781 (1981).
- 6) S. Umezawa and T. Tsuchiya, "Aminoglycoside Antibiotics," ed by H. Umezawa and I. R. Hooper, Springer-Verlag, Berlin, Heidelberg, New York, (1982) p. 37—110.
- 7) T. Tsuchiya, S. Sakamoto, T. Yamasaki, S. Umezawa, and H. Umezawa, J. Antibiot., 35, 639 (1982).
- 8) T. Tsuchiya and T. Shitara, Carbohydr. Res., 109, 59 (1982).
- 9) T. Tsuchiya, T. Kishi, S. Kobayashi, Y. Kobayashi, S. Umezawa, and H. Umezawa, Carbohydr. Res., 104, 69 (1982).
- 10) T. Yamasaki, T. Tsuchiya, and S. Umezawa, J. Antibiot., 31, 1233 (1978).
- 11) Y. Takagi, O. Kawashima, T. Tsuchiya, H. Sano, and S. Umezawa, *Bull. Chem. Soc. Jpn.*, **49**, 3108 (1976).
- 12) M. Arimori and T. Kawasaki, *Chem. Pharm. Bull.*, 18, 677 (1970).
- 13) M. H. Munro, R. M. Stroshane, and K. L. Rinehart, Jr., J. Antibiot., 35, 1331 (1982).
- 14) W. Voelter, E. Breitmaier, E. B. Rathbone, and A. M. Stephen, *Tetrahedron*, **29**, 3845 (1973) and references cited therein.
- 15) S. Umezawa, T. Tsuchiya, and K. Tatsuta, *Bull. Chem. Soc. Jpn.*, **39**, 1235 (1966).
- 16) T. Usui, T. Tsuchiya, and S. Umezawa, J. Antibiot., **31**, 991 (1978).
- 17) W. J. Polglase, J. Org. Chem., 27, 1923 (1962).
- 18) T. J. de Boer and H. J. Backer, *Org. Synth.*, Coll. Vol. 4, 250 (1963).
- 19) H. Paulsen, P. Stadler, A. Banaszek, and F. Toedter, *Chem. Ber.*, **110**, 1908 (1977).

^{*} The elemental analyses fluctuated in every sample possibly on account of the difference of uptake of CO₂ from the air, but the data showed no much deviation from the values as the monocarbonate.